新华医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：人脑工程（脑机接 口）、民营医院、医疗器械、合成生物、人工智能等。 截至9月30日，新华医疗股东户数3.87万，较上期减少1.44%；人均流通股15610股，较上期增加1.46%。 2025年1月-9月，新华医疗实现营业收入69.78亿元，同比减少6.00%；归母净利润4.34亿元，同比减少 29.61%。 分红方面，新华医疗A股上市后累计派现9.63亿元。近三年，累计派现6.07亿元。 机构持仓方面，截止2025年9月30日，新华医疗十大流通股东中，华宝中证医疗ETF（512170）位居第 三大流通股东，持股1373.28万股，相比上期减少236.04万股。香港中央结算有限公司位居第四大流通股 东，持股868.91万股，相比上期增加76.89万股。国联优势产业混合A（014329）位居第七大流通股东， 持股486.61万股，为新进股东。南方中证1000ETF（512100）位居第八大流通股东，持股443.44万股， 为新进股东。 1月21日，新华医疗盘中上涨2.05%，截至10:29，报16.42元/股，成交1.20亿元，换手率1.22 ...

证券日报网讯1月20日，新华医疗（600587）在互动平台回答投资者提问时表示，公司将持续聚焦主 业、稳健经营，推进核心业务升级与发展布局。 ...

Core Viewpoint - Xinhua Medical (600587) has indicated that the number of shareholders as of December 31 will be available in the company's regular reports, and there will be no earnings forecast in the annual report [1] Group 1 - The company responded to investor inquiries on its interactive platform [1] - The company will provide shareholder information in its periodic reports [1] - There will be no earnings forecast for the annual report [1]

Core Viewpoint - Xinhua Medical aims to achieve its first sales of medical linear accelerators in Europe by 2025, marking a significant milestone for the company in the international market [2] Company Summary - The company has received EU MDR-CE certification for two models of its medical linear accelerators, XHA600E and XHA1400, making it the first domestic enterprise in this category to obtain such certification [2]

Core Viewpoint - Xinhua Medical (600587) indicated that its controlling shareholder will consider the overall capital market conditions, stock price fluctuations, and personal funding arrangements to strategically advance subsequent share buybacks under compliance [1] Group 1 - The company is planning to execute share buybacks based on market conditions [1] - The controlling shareholder's actions will be influenced by the company's stock price movements [1] - Compliance with regulations will be a priority in the execution of the buyback plan [1]

证券日报网讯 1月16日，新华医疗在互动平台回答投资者提问时表示，截至2025年11月，公司控股股东 已累计增持386.38万股，增持金额6011.35万元。控股股东将继续根据资本市场整体情况、公司股价波动 及自身资金安排，在合规前提下择机推进后续增持工作。 （编辑 丛可心） ...

Group 1 - The company is developing an AI technology platform that enhances various medical equipment, including laboratory devices, pharmaceutical equipment, and in vitro diagnostic devices [2] - The latest AI intelligent technology is being integrated into the company's equipment, indicating a commitment to advancing technology and industry integration [2] - The company plans to continue deepening the integration of technology with its industrial applications in the future [2]

（编辑 丛可心） 证券日报网讯 1月16日，新华医疗在互动平台回答投资者提问时表示，公司管理层正在全面审视各项业 务布局，对于中帜生物项目，公司会结合战略规划和投资收益进行审慎评估，后续如有重大进展，公司 将严格按照信息披露要求及时公告。 ...

证券日报网讯1月16日，新华医疗（600587）在互动平台回答投资者提问时表示，公司将根据华检医疗 股票价格波动情况及资本市场整体趋势实施减持计划。 ...

格隆汇1月16日丨新华医疗(600587.SH)在投资者互动平台表示，公司影像设备具备AI影像辅助诊断功 能。 ...